期刊
BIOMOLECULES
卷 13, 期 9, 页码 -出版社
MDPI
DOI: 10.3390/biom13091307
关键词
prebiotics; intestinal microbiome; short chain fatty acids; butyrate; functional foods; Type 2 Diabetes Mellitus
Hypoglycemic medications that can be used together with prebiotics and functional foods can reduce the burden of metabolic diseases, particularly Type 2 Diabetes Mellitus. The combination treatment improves the gut microbiome by increasing the diversity of microbial niches and promoting the growth of beneficial bacteria. This leads to higher levels of short-chain fatty acids, which provide energy sources for the gut microbiome and improve intestinal health. The treatment also improves gut barrier integrity and reduces the risk of developing Type 2 Diabetes Mellitus.
Hypoglycemic medications that could be co-administered with prebiotics and functional foods can potentially reduce the burden of metabolic diseases such as Type 2 Diabetes Mellitus (T2DM). The efficacy of drugs such as metformin and sulfonylureas can be enhanced by the activity of the intestinal microbiome elaborated metabolites. Functional foods such as prebiotics (e.g., oligofructose) and dietary fibers can treat a dysbiotic gut microbiome by enhancing the diversity of microbial niches in the gut. These beneficial shifts in intestinal microbiome profiles include an increased abundance of bacteria such as Faecalibacterium prauznitzii, Akkermancia muciniphila, Roseburia species, and Bifidobacterium species. An important net effect is an increase in the levels of luminal SCFAs (e.g., butyrate) that provide energy carbon sources for the intestinal microbiome in cross-feeding activities, with concomitant improvement in intestinal dysbiosis with attenuation of inflammatory sequalae and improved intestinal gut barrier integrity, which alleviates the morbidity of T2DM. Oligosaccharides administered adjunctively with pharmacotherapy to ameliorate T2DM represent current plausible treatment modalities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据